Skip to content

What We Do

At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers.  We envision a world where drug discovery is not left to chance but guided by artificial intelligence to make therapeutic development smarter, more precise, and ultimately faster.  

With our RubrYc Discovery Platform we are pursuing hard-to-drug targets with greater potential and less competition.  We have nine immuno-oncology candidates in our pipeline, including those for the potential treatment of solid tumors, glioblastoma, and head and neck cancers.

An essential challenge to developing antibody drugs is traditional discovery technologies employ a high degree of randomness. Creating an antibody with a set of desired qualities requires repeated attempts until the optimal  result is achieved, often by chance. While this approach has yielded valuable therapeutics in the past, that outcome is rare, with fewer than 1 in 1,000 targets ever reaching the clinic. Traditional antibody development methods are time consuming, costly, and we believe ultimately produce fewer potentially life-saving drugs than possible.  We believe that our RubrYc Discovery Platform offers the precision required to solve this problem, while also identifying the most challenging targets.

iBio’s patented antibody discovery technology employs an artificial intelligence (AI) engine designed to actively guide the discovery process directly to a desired result. Our RubrYc Discovery Platform is comprised of three main components:

  • An AI-driven Epitope Engineering Engine, which enables the active steering of antibody discovery to desirable binding sites on the target protein
  • A modern Antibody Library of fully human sequences and a clinically validated framework
  • An Antibody Optimizer for generating functionally enriched libraries from a template antibody

By moving beyond traditional “trial-and-error” methods, we believe our platform will enable us to bring cancer therapeutics based on previously undruggable proteins into the clinic faster and more cost-effectively – both for our own development and in partnership with others.

Our Team

Martin Brenner headshot
Robert Lutz
Nick DeLong headshot
Matthew Greving headshot
Dillon Phan headshot